Novo Nordisk reported mixed Q2 results with 7% adjusted net sales growth driven by its obesity segment, especially the Wegovy pill, supported by strong US demand and new markets. Despite this, shares dropped 6% due to margin pressure from U.S. price reductions and some pipeline setbacks. The company maintains strong profitability, free cash flow, and a solid balance sheet, enabling continued R&D investment and shareholder returns. Conservative valuation models suggest the stock is undervalued with at least 25% upside potential and a target price of $57 per share.
Novo Nordisk has received a Sell rating due to declining profits, weak revenue growth, and operational challenges despite its leading semaglutide product. The company's 2026 guidance predicts flat to negative sales and operating profit growth, contra...
Eli Lilly and Novo Nordisk both beat Q2 estimates and raised their full-year outlooks, but investors favored Lilly, boosting its shares while punishing Novo. Lilly leads the obesity drug market with a 60.9% U.S. share, driven by strong sales of Mounj...
The District Court of The Hague granted Novo Nordisk a preliminary injunction against Ceban Ziekenhuisfarmacie B.V., stopping the sale of an unapproved compounded semaglutide nasal spray that infringes Novo Nordisk's patent. The court ruling protects...
